These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 26205091

  • 1. Immunoregulatory effects of sirolimus vs. tacrolimus treatment in kidney allograft recipients.
    Gong N, Chen Z, Wang J, Fang A, Li Y, Xiang Y, Ming C, Zhang W.
    Cell Immunol; 2015 Oct; 297(2):87-93. PubMed ID: 26205091
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The advantage of Sirolimus in amplifying regulatory B cells and regulatory T cells in liver transplant patients.
    Song J, Du G, Chen W, Bao P, Li B, Lu Q, Shi B.
    Eur J Pharmacol; 2020 Feb 15; 869():172872. PubMed ID: 31846626
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients.
    Chu ZQ, Ji Q.
    Transplant Proc; 2013 Feb 15; 45(1):153-6. PubMed ID: 23375290
    [Abstract] [Full Text] [Related]

  • 6. Both tacrolimus and sirolimus decrease Th1/Th2 ratio, and increase regulatory T lymphocytes in the liver after ischemia/reperfusion.
    Arias-Diaz J, Ildefonso JA, Muñoz JJ, Zapata A, Jiménez E.
    Lab Invest; 2009 Apr 15; 89(4):433-45. PubMed ID: 19188906
    [Abstract] [Full Text] [Related]

  • 7. Comparison of regulatory T cells and FoxP3-positive T-cell subsets in the peripheral blood of renal transplant recipients with sirolimus versus cyclosporine: a preliminary study.
    Zhao T, Yang C, Qiu Y, Xue Y, Zhao Z, Song D, Qiu Y, Ma Z, Yang B, Xu M, Rong R, Zhu T.
    Transplant Proc; 2013 Apr 15; 45(1):148-52. PubMed ID: 23375289
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients.
    Hendrikx TK, Velthuis JH, Klepper M, van Gurp E, Geel A, Schoordijk W, Baan CC, Weimar W.
    Transpl Int; 2009 Sep 15; 22(9):884-91. PubMed ID: 19453998
    [Abstract] [Full Text] [Related]

  • 10. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal.
    Heilman RL, Cortese C, Geiger XJ, Younan K, Wadei HM, Mai ML, Reddy KS, Gonwa TA.
    Transplantation; 2012 Jan 15; 93(1):47-53. PubMed ID: 22067270
    [Abstract] [Full Text] [Related]

  • 11. Successful resolution of inflammation and increased regulatory T cells in sirolimus-treated post-transplant allograft hepatitis.
    Ekong UD, Mathew J, Melin-Aldana H, Wang D, Alonso EM.
    Pediatr Transplant; 2012 Mar 15; 16(2):165-75. PubMed ID: 22360400
    [Abstract] [Full Text] [Related]

  • 12. Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation.
    van de Wetering J, Koumoutsakos P, Peeters A, van der Mast BJ, de Kuiper P, IJzermans JN, Weimar W, Baan CC.
    Clin Transplant; 2011 Mar 15; 25(1):40-6. PubMed ID: 20636406
    [Abstract] [Full Text] [Related]

  • 13. Combined therapy of CD4(+)CD25(+) regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice.
    Ma A, Qi S, Wang Z, Massicotte E, Dupuis M, Daloze P, Chen H.
    Int Immunopharmacol; 2009 May 15; 9(5):553-63. PubMed ID: 19539558
    [Abstract] [Full Text] [Related]

  • 14. Cellular and molecular immune profiles in renal transplant recipients after conversion from tacrolimus to sirolimus.
    Gallon L, Traitanon O, Sustento-Reodica N, Leventhal J, Ansari MJ, Gehrau RC, Ariyamuthu V, De Serres SA, Alvarado A, Chhabra D, Mathew JM, Najafian N, Mas V.
    Kidney Int; 2015 Apr 15; 87(4):828-38. PubMed ID: 25354238
    [Abstract] [Full Text] [Related]

  • 15. The role of regulatory B cells (Bregs) in the Tregs-amplifying effect of Sirolimus.
    Song J, Xiao L, Du G, Gao Y, Chen W, Yang S, Fan W, Shi B.
    Int Immunopharmacol; 2016 Sep 15; 38():90-6. PubMed ID: 27258186
    [Abstract] [Full Text] [Related]

  • 16. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 17. Immunophenotyping of peripheral immunoregulatory as well as Th17A and Th22 cell subpopulations in kidney transplant recipients under belatacept or cyclosporine treatment.
    Furuzawa-Carballeda J, Bostock IC, Lima G, Mancilla-Urrea E, Mondragón G, Reyes-Acevedo R, Chevaile A, Morales-Buenrostro LE, Llorente L, Alberú J.
    Transpl Immunol; 2014 Mar 15; 30(2-3):107-13. PubMed ID: 24561014
    [Abstract] [Full Text] [Related]

  • 18. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J, Bono MR, Fierro A, Iñiguez R, Zehnder C, Rosemblatt M, Calabran L, Herzog C, Benavente D, Aguiló J, Pefaur J, Alba A, Ferrario M, Simon W, Contreras L, Buckel E.
    Transplant Proc; 2008 Nov 15; 40(9):3223-8. PubMed ID: 19010240
    [Abstract] [Full Text] [Related]

  • 19. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 20. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, Chevaile-Ramos JA, Layseca-Espinosa E, González-Amaro R, Portales-Pérez D.
    Transpl Immunol; 2009 May 15; 21(1):43-9. PubMed ID: 19233271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.